Bone Health in Prostate Cancer, A Conversation with Neal Shore and Oliver Sartor
Neal Shore and Oliver Sartor have a conversation on bone-targeted agent therapies in prostate cancer, specifically focusing on the ALSYMPCA phase three trial; the design, findings, the addition of radium 223 and what this trial has led to today. They review a few other current ongoing trials including the PEACE III single arm trial and other current approaches in understanding combination therapies in bone health.
